Oral GLP-1 Drugs: How the New Weight Loss Pills Work

How the New Oral GLP-1 Weight Loss Medications Work

How the New Oral GLP-1 Weight Loss Medications Work
Getty Images; Everyday Health

A weekly injection is no longer the only way to reap the obesity management and weight loss benefits of glucagon-like peptide-1 (GLP-1) medications. The U.S. Food and Drug Administration (FDA) has approved two oral GLP-1 options: Wegovy (semaglutide) and Foundayo (orforglipron). Both offer a needle-free approach to managing weight and supporting metabolic health.

Learn about how each of those FDA-approved oral weight loss medications work and alternative pill options to consider.

GLP-1 Drugs Affect Your Gut and Brain

All GLP-1 medications — including oral pills and injections — work by mimicking GLP-1, a natural hormone your body releases after a meal. It helps control appetite, digestion, and blood sugar.

Synthetic forms of the hormone, including newer dual GIP/GLP-1 drugs, can support weight loss and weight management in several ways: They can help you feel fuller for longer, slow digestion, and quiet persistent thoughts about food that some people refer to as food noise.

These medications also “enhance insulin secretion,” which can result in better blood sugar control in addition to weight loss, says Sara Velayati, MD, an obesity medicine specialist at Montefiore Einstein’s Fleischer Institute Medical Weight Center in New York. By acting on your brain, stomach, and blood sugar systems at the same time, GLP-1 medications can support meaningful weight loss and improve metabolic health over time, she says.

GLP-1s and Your Stomach: The Challenge

GLP-1 medications are traditionally available as injections because your stomach can destroy them if you take them by mouth. These drugs are peptides, which are short chains of amino acids that your body treats like food. Ingested on their own, these peptides are broken down by stomach acid and digestive enzymes before they reach your bloodstream, negatively impacting the overall amount your body can absorb and use.

The peptide nature of this hormone is why developing effective oral versions of GLP-1 medications has been so challenging, says Dr. Velayati.

Oral Semaglutide

In December, 2025, the FDA approved Wegovy (semaglutide) as a daily GLP-1 pill for adults who are overweight or have obesity and at least one related health condition.

This new form gets around your gut’s natural defenses with a “permeation enhancer” called SNAC, letting the medication work without a needle. When the pill reaches your stomach, SNAC temporarily raises the local pH, preventing the tablet from breaking down too quickly, says Velayati.

Because the gut is a challenging environment for absorption, oral semaglutide doses are much higher — 25 milligrams (mg) daily — than standard 2.4-mg weekly injections.

Even though the oral dose is higher, only a tiny fraction actually enters the bloodstream. Velayati says your body absorbs only about 0.4 to 1 percent of semaglutide taken by mouth. “So if you take 100 units, less than one actually reaches the bloodstream. But that tiny amount is still enough to have a meaningful clinical effect,” she says. The higher oral dose of semaglutide ensures enough medication survives the stomach acid.

Dosage Timing

If you’re thinking about trying the new weight loss pill instead of the weekly injection, you may need to rethink your morning routine. Unlike the injection, which can be given at any time, the pill requires a strict fasting window. You need to take it on an empty stomach with no more than 4 ounces (oz) of plain water and wait at least 30 minutes before eating breakfast or drinking a cup of coffee.

“The SNAC matrix changes the pH locally where it hits the stomach lining, and this allows absorption,” says W. Timothy Garvey, MD, professor of medicine and director of the University of Alabama at Birmingham’s Diabetes Research Center. “Food prevents this interaction.”

If you eat too soon after taking the pill, food surrounds it in your stomach. That keeps the medication from touching your stomach lining the way it needs to in order to work, says Velayati. Similarly, drinking too much water can dilute the SNAC buffer, and the medication will simply be digested and wasted.

Small-Molecule Drugs

On April 1, the FDA approved the GLP-1 Foundayo (orforglipron) for adults with obesity or who are overweight and have weight-related health issues.

 It’s also the only GLP-1 pill for weight loss that doesn’t carry any restrictions around fasting or when you can take it.
That’s because orforglipron is among the next generation of weight loss pills — alongside aleniglipron and other experimental drugs — which scientists call small-molecule drugs. These are much more stable than peptide-based drugs.

Peptide medications have a large molecular weight and mimic your body’s delicate regulatory signals. “Small molecules are chemically synthesized and designed to interact with receptors and enzymes,” says Dr. Garvey. “They’re smaller in molecular weight than peptide medications that mimic or interfere with endogenous bioregulatory peptides.”

Think of it this way: While a peptide is like a fragile piece of paper that dissolves in the rain, a small molecule is like a tiny pebble, sturdy enough to survive the digestive storm.

Velayati says the natural stability of these newer drugs allows them to survive stomach acid without a special chemical enhancer (like SNAC). Because your body doesn’t try to “digest” these molecules, other drugs in this class, such as Foundayo, likely won’t require strict fasting or perfect timing either.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. GLP-1 Agonists. Cleveland Clinic. July 3, 2023.
  2. Hayashi D et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. November 17, 2023.
  3. Collins L et al. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. February 29, 2024.
  4. FDA Approves Novo Nordisk’s Wegovy Pill, the First and Only Oral GLP-1 for Weight Loss in Adults. PR Newswire. December 22, 2025.
  5. What Is SNAC in Oral Semaglutide? Biopharma PEG. September 7, 2023.
  6. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. April 1, 2026.
  7. Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. The New England Journal of Medicine. November 6, 2025.
Sean-Hashmi-bio

Sean Hashmi, MD

Medical Reviewer

Sean Hashmi, MD, is an experienced nephrologist and obesity medicine specialist based in Southern California. As the regional director for clinical nutrition and weight management ...

Susan Jara

Author

Susan Jara is a health communications strategist and writer with more than 15 years of experience transforming complex medical information into clear, accurate, and engaging conten...